Guggenheim maintains Amgen stock rating after lung cancer data
Guggenheim kept a Neutral rating and $378 price target on Amgen (AMGN) after positive lung cancer trial data. The stock trades near its 52-week high. The trial showed a 58% reduction in death risk for a combination therapy. Guggenheim noted the data supports its estimates but maintained the Neutral rating due to valuation. Other analysts have raised price targets, with some projecting strong Q3 2026 earnings.
How this was made
The 30-second read
Why it matters
The Phase 3 data represent a material clinical milestone that could expand Amgen's oncology franchise and drive share price appreciation.
Market read
Amgen's new trial data is the primary catalyst for potential short‑term price movement and longer‑term growth expectations.
What to watch
Potential regulatory hurdles and competition from other immunotherapy candidates could temper upside.
Background
The article summarizes analyst reactions and price target updates following Amgen's presentation at the 2026 ESMO Congress.
Ticker impact
Guggenheim maintained a Neutral rating on Amgen after the Phase 3 DeLLphi-305 trial data showed a 58% mortality reduction versus Imfinzi alone.
likely upside as the market prices in the survival benefit and expanded market opportunity.
The trial results are a primary disclosure with a large efficacy signal; analysts are raising price targets, indicating strong market reaction potential.
Market effects
Biotech sector may see broader optimism for oncology pipelines.
U.S. biotech stocks could experience modest gains.
International investors tracking Amgen may adjust exposure to cancer therapeutics.
Counterpoint
Some investors may remain cautious if the trial data does not translate into near‑term sales.
Key entities
- analystGuggenheim
Maintained Neutral rating and $378 price target on Amgen.
- analystOppenheimer
Raised price target to $480 after trial results.
